GNPX Stock Performance, Insider Transaction and News

GNPX - Genprex, Inc.

Market Cap	42.83M	P/E	-	EPS this Y	74.40%	Ern Qtrly Grth	-
Income	-30.86M	Forward P/E	-1.76	EPS next Y	51.80%	50D Avg Chg	-14.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-34.00%
Dividend	N/A	Price/Book	2.03	EPS next 5Y	-	52W High Chg	-73.00%
Recommedations	2.30	Quick Ratio	2.07	Shares Outstanding	1.91M	52W Low Chg	4.00%
Insider Own	0.85%	ROA	-108.64%	Shares Float	1.88M	Beta	-0.63
Inst Own	6.56%	ROE	-207.88%	Shares Shorted/Prior	69.95K/64.89K	Price	0.72
Gross Margin	-	Profit Margin	-	Avg. Volume	603,369	Target Price	165.00
Oper. Margin	-	Earnings Date	May 22	Volume	561,426	Change	-3.87%

Healthcare | Biotechnology | United States

About Genprex, Inc.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Genprex, Inc. News

04/09/24	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
04/04/24	Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
04/03/24	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
04/02/24	Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
03/22/24	Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03/19/24	Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03/12/24	Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
03/06/24	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
02/07/24	Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
02/06/24	Genprex to Present at Upcoming BIO CEO & Investor Conference
02/05/24	Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
01/31/24	Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
01/05/24	Genprex Provides Business Update and Outlook for 2024
11/23/23	Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer
11/03/23	Genprex to Present at BIO-Europe 2023
11/01/23	Genprex to Present at BIO-Europe 2023 Conference
10/20/23	Genprex Schedules, Hosts Virtual Key Opinion Leader Event
10/20/23	Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
10/06/23	Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference
10/04/23	Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GNPX Chatroom

SWEETHEART100 Posted - 1 hour ago

$GNPX The minute this garbage goes past $5 I’ll be thankful to get my money back

SWEETHEART100 Posted - 1 hour ago

$GNPX this stock was $7.34 when it did the reverse split. what a freaking disaster

SWEETHEART100 Posted - 1 hour ago

$GNPX this stock is getting effing ridiculous… hey CEOs of GNPX! Do something to support your stock price or you’ll have to fo another reverse split!!!

Get_Busy_Living Posted - 2 hours ago

$GNPX back under a buck soon. Even after a 40-1 reverse split. This is by far the biggest scam on all of NASDAQ.

Brandon21k Posted - 6 hours ago

$GNPX insiders are always going to say they're positive cuz they want you to buy their f****** stock! This thing is an absolute piece of s*** down 50% in the last 30 days! What's bullish about that? Somebody please tell me!

POSGNPX Posted - 12 hours ago

$GNPX I hope everybody understand

POSGNPX Posted - 14 hours ago

$GNPX I have about 4000 acres for sale on the moon if anybody would like to purchase it

POSGNPX Posted - 17 hours ago

$GNPX this is .058 cents share : remember there was a 40 to 1 split

SWEETHEART100 Posted - 19 hours ago

$GNPX why is it dropping so much on no news?

Optimisticinvestor777 Posted - 20 hours ago

$GNPX No volume! I’m buying, probably going to the dark pool but can’t resist! Doubled my position today!

Makessense Posted - 20 hours ago

$GNPX Don’t know who the insiders are in below quote but did read this on Stock Invest US. Today published. Insiders are very positive buying more shares than they are selling in Genprex Inc. In the last 100 trades there were 14.93 million shares bought and 1.08 million shares sold. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.

keremoner Posted - 21 hours ago

$GNPX yup, keep on listening to idiots like @GennyLover instead of those trying to warn you of the realities of trial stage biotech.

Optimisticinvestor777 Posted - 21 hours ago

$GNPX all time low, maybe it will go up soon!

Brandon21k Posted - 22 hours ago

$GNPX seems like a piece of shit to me. Down 50% in a month.

Optimisticinvestor777 Posted - 1 day ago

$GNPX seems bullish to me!

Makessense Posted - 2 days ago

$GNPX These data have high therapeutic significance, suggesting that one of the anti-tumor mechanisms of quar oze action in patients is the suppression of cancer cell metabolism resulting in cancer cell death.

POSGNPX Posted - 3 days ago

$GNPX what a great board Director

eoJC Posted - 3 days ago

$GNPX look at all the insider buying… Oh, wait a second, that’s a different company lol. Nice job Confer and RV

Makessense Posted - 3 days ago

$GNPX https://www.genprex.com/downloads/2024-aacr-poster-mechanism-of-nprl2-gene-therapy-induced-anti-tumor-immunity-in-kras-stk11mt-apd1-resistant-metastatic-nsclc.pdf

Makessense Posted - 3 days ago

$GNPX https://www.genprex.com/downloads/2024-aacr-poster-quaratusugene-ozeplasmid-mediated-tusc2-upregulation-in-eml4-alk-bearing-non-small-cell-lung-carcinoma-can-induce-cellular-apoptosis.pdf

Makessense Posted - 3 days ago

$GNPX https://www.genprex.com/downloads/2024-aacr-poster-tumor-suppressor-gene-tusc2-suppresses-energy-metabolism-in-lung-cancer-cells-with-opposite-effects-in-normal-bronchial-epithelial-cells.pdf

Makessense Posted - 3 days ago

$GNPX Down on only 10K Volume.

Jpeel1972 Posted - 4 days ago

$GNPX this is only getting worse each day. Offerings and splits make it irreversible

VIPTrades009 Posted - 4 days ago

$YYAI Hope $GV gives a similar move soon….. $GNPX

GuyC22 Posted - 4 days ago

$GNPX I think like many people watching, will go in big if a bottom is ever confirmed.

Optimisticinvestor777 Posted - 5 days ago

$GNPX added more on the drop!

Makessense Posted - 5 days ago

$GNPX As far as I'm concerned, perfect moments to buy some additional pieces.

Mystock9 Posted - 5 days ago

$GNPX This has completed RS. Very low float. Are there any potential knocking.

Mystock9 Posted - 5 days ago

$GNPX Any suggestions on this. Do you think this will rise.

Jpeel1972 Posted - 6 days ago

$GNPX yesterday was disappointing. 3 times normal volume and it ended flat.

Analyst Ratings

HC Wainwright & Co.	Buy	Apr 4, 24
HC Wainwright & Co.	Buy	Apr 3, 24
HC Wainwright & Co.	Buy	Mar 25, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Varner John Rodney	Chairman, President.. Chairman, President and CEO	Apr 21	Buy	1.055	19,000	20,045	20,800	04/24/23
VACZY CATHERINE M	EVP GC Chief Strateg.. EVP GC Chief Strategy Officer	Apr 21	Buy	1.0739	20,000	21,478	265,000	04/24/23
Confer Ryan M.	Chief Financial Offi.. Chief Financial Officer	Jul 28	Option	0.015	116,973	1,755	190,499	08/01/22